FDA Cold-Cox Merck; Arcoxia “Not Approvable” For Osteoarthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency indicates more data is needed on benefit-to-risk profile of the COX-2 inhibitor, but Merck is mum on whether it will continue to pursue approval.
You may also be interested in...
PPI/NSAID Combinations Could Have Smoother Route To Approval After Review Division Harmonization
FDA will ask its Gastrointestinal Drugs Advisory Committee at a Nov. 4 meeting whether it agrees that endoscopically diagnosed ulcers are an appropriate surrogate endpoint, which would make large, pre-approval GI outcomes studies unnecessary.
PPI/NSAID Combinations Could Have Smoother Route To Approval After Review Division Harmonization
FDA will ask its Gastrointestinal Drugs Advisory Committee at a Nov. 4 meeting whether it agrees that endoscopically diagnosed ulcers are an appropriate surrogate endpoint, which would make large, pre-approval GI outcomes studies unnecessary.
No Big Surprise For Novartis: Prexige Is “Not Approvable” At FDA
Firm now plans to discuss path forward, which may include additional trials of the COX-2 inhibitor, with FDA, Novartis tells "The Pink Sheet" DAILY.